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Sharpening the focus on pancreatic resection margins
Standardization and removal of variability are key components in the delivery of quality healthcare. An
example familiar to most surgeons is the redefinition of what constituted a positive resectionmargin in rectal
cancer. This resulted in a radical change in the approach to this disease. In this issue of HPB, Maksymov et al.
highlight a similar concept in pancreatic cancer, building on the initial work previously published inHPB by
Verbeke and colleagues. The authors elegantly highlight the considerable variation that exists amongst
clinicians and professional bodies in defining ‘what constitutes a positive resection margin in pancreatic
cancer?’ Using a small group of 25 patients who underwent a Whipples resection for pancreatic adenocar-
cinoma, the authors have demonstrated considerable variation in reported R1 rates when radial margins and
distances of tumour from a resection margin or surface are not assessed in a standardized way. The
importance of this for the pancreatic surgeon is that by using such standardized methodology the R1 rates
following pancreaticoduodenctomy will increase in most series from 20–35% up to 65–80%. For this author,
these consistently replicated results create significant equipoise with regard to the standard approach to
resectable pancreatic cancer. Surely it is time for a randomized controlled trial comparing neoadjuvant
therapy vs. standard of care for resectable pancreatic cancer. Are we simply 20 years behind the colorectal
surgeons?
Saxon Connor
TACE – Good radiological response does not necessarily equate with
improved overall survival
The treatment options for non-resectable primary hepatocellular carcinoma (HCC) are limited. Trans
arterial chemoembolization (TACE) is a therapy which has achieved considerable popularity as a means for
treating non-resectable HCC but with variable evidence supporting its use. One of the issues with TACE is
how to evaluate treatment results and this is the subject of a retrospective study from Columbus, Ohio in this
month’s edition of HPB. Henry and colleagues looked back at 104 patients who received TACE over a 10-year
period in their institution. After exclusions, 78 patients were analysed. Around a third of these had a ‘best
radiological response’ to TACE meaning that their tumour either disappeared or showed reduction in size
and no new areas of enhancement compatible with untreated HCC. Patients who had a good radiological
response went on to have a better progression free survival. In overall terms, there was no difference in
outcome between those patients who had a good radiological response or poor response to TACE. The
authors explain this apparent anomaly by suggesting that many of the prognostic factors associated with
outcome in HCC are related to the extent of underlying liver disease and function rather than specific
characteristics of the tumour itself. How do we interpret these data in terms of a clinical role for TACE?Well,
we can say with some confidence that TACE is good at controlling the growth of HCC and has a tumoristatic
or tumoricidal effect. This has value in situations where we may wish to stop growth of HCCs to allow a
patient to receive other treatment such as patients with HCC awaiting liver transplant. We can also say that
despite being able to hold tumour growth, a good response from TACE does not increase overall survival.
This implies that TACE needs to be combined with another therapy. There are currently examples of
combining TACE with ablation and TACE with biological therapies and it will be interesting to see if these
offer a superior survival benefit compared with TACE alone.
Stephen Wigmore
Something else to make laparoscopic cholecystectomy difficult
Once common bile duct stones are cleared by endoscopic retrograde cholangiography and sphincterotomy
(ERC/ES), a prompt subsequent laparoscopic cholecystectomy (LC) is optimal management for eligible
patients but is it also optimal for the operating surgeon? Perhaps not! Reinders et al. convincingly reveal that
a LC after ERC/ES takes longer, is technically more difficult and probably has higher conversion and
complication rates. To determine this, they compared 93 patients who underwent LC after a previous
ERC/ES (47 early, 46 late – LANS trial) against 83 patients who underwent elective LC for uncomplicated
gallstone disease. Although the complications rates reported were not significantly different (12.9% prior
ERC vs 9.6% elective) they probably were in practical terms, as in the elective LC group, 2 patients had
iatrogenic bowel injuries and one eventually died from abdominal sepsis. Such issues should be exceedingly
rare for elective LC today. This is the first such published cohort study and it supports previous retrospective
studies of higher complication and conversion rates for LC after ERC/ES. The authors suggest that LC after
ERC/ES should be performed by the most experienced laparoscopic surgeons but that is unlikely to occur
worldwide. Instead, surgeons should share and emphasize these realities with patients during informed
consent and be prepared for what lies ahead.
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